Document is current
Any future updates will be listed below
-
Authors
Querin, Giorgia
Lenglet, Timothée
Debs, Rabab
Stojkovic, Tanya
Behin, Anthony
Salachas, François
Le Forestier, Nadine
Amador, Maria Del Mar
Bruneteau, Gaëlle
Laforêt, Pascal
Blancho, Sophie
Marchand-Pauvert, Véronique
Bede, Peter
Hogrel, Jean-Yves
Pradat, Pierre-François
-
Funding
Funding for this research was provided by:
AFM-Téléthon
- License Information
-
More Information
Article History
Received: 6 September 2020
Revised: 19 November 2020
Accepted: 19 November 2020
First Online: 2 January 2021
Compliance with ethical standards
:
: This study was sponsored by the Association française contre les myopathies (AFM-Téléthon). Dr. Giorgia Querin, Dr. Timothée Lenglet, Dr. Rabab Debs, Dr. Tanya Stojkovic, Dr. Anthony Behin, Dr. François Salachas, Dr. Nadine Le Forestier, Dr. Maria del Mar Amador, Dr. Gaëlle Bruneteau, Dr. Sophie Blancho, Dr. Véronique Marchand-Pauvert: report no disclosures. Prof Pascal Laforêt receives funding for research and as an advisor or speaker from Sanofi Genzyme and Spark Therapeutics. Dr. Peter Bede is supported by the Health Research Board (HRB EIA-2017-019), the Andrew Lydon scholarship, the Irish Institute of Clinical Neuroscience (IICN), the Irish Motor Neuron Disease Association (IMNDA) and the Iris O'Brien Foundation. Dr. Jean-Yves Hogrel is co-inventor of the Myogrip and MyoPinch devices and did consultancy for Biogen and Sarepta. Dr Pierre- François Pradat receives funding as an advisor and speaker from Biogen.
